Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Anti-PD-1 Therapy Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Multi-center Trial (SCR-ESCC-01)

NCT05978193 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT05978193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05978193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Anti-PD-1 Therapy Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Multi-center Trial (SCR-ESCC-01)
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2023
Completion date
January 1, 2028
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, esophageal squamous cell carcinoma, metastatic esophageal squamous cell carcinoma